De novo purine metabolism is a metabolic vulnerability of cancers with low p16 expression
N. K. Tangudu, R. Buj, H. Wang…·K. M. Aird
This study identifies de novo purine metabolism as a vulnerability in cancers with low p16 expression, showing sensitivity to anti-folate drugs like methotrexate.